Producer
Ceva Santé Animale
Ceva Santé Animale (Libourne, France; private; ~€1.7B revenue) is the 5th largest animal health company globally and a major poultry vaccine manufacturer. Ceva produces MAFIVAC AI vaccines, VECTORMUNE ND+AI recombinant vaccines, and other poultry biologicals. Ceva has significant manufacturing in France (Libourne + Pau), Spain, and the US. In 2022-2024, Ceva supplied emergency AI vaccines to France's commercial duck industry during HPAI H5N1 outbreaks.
3
Inputs supplied
3
Goods downstream
4
Facilities
0
Stories
What they make
3 inputs Ceva Santé Animale supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Ceva Santé Animale makes — pick one to see the full supply chain.
Where they make it
4 facilities
Ceva Sante Animale - Angers, France →
FR7,000 sqm facility; swine, poultry, ruminant vaccines; France production campus
Ceva Sante Animale - Monor, Hungary →
HU7,000 sqm new plant; fermentation-based multicomponent inactivated vaccines; expanding European hub
Ceva Santé Animale Libourne HQ & R&D →
FRLibourne, Gironde · pharmaceutical_plant
Ceva's global headquarters and a major production site for poultry biologics including CEVAC MD Rispens and bivalent MDV vaccines. Ceva claims the original European Rispens lineage. Libourne, near Bordeaux, is the nerve center of a poultry vaccine company that punches above its weight given its market focus specialization on poultry biologics vs. the diversified multinational competitors.
Ceva Santé Animale Libourne Headquarters and Manufacturing →
FRGironde, Nouvelle-Aquitaine · lab
Ceva's Libourne France headquarters and primary biologics manufacturing site. Produces MAFIVAC AI vaccines and recombinant poultry biologicals. Ceva supplied emergency AI vaccines to French duck producers 2022-2024.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Poultry Vaccines & Biologics
40%Swine Health
25%Ruminant Health
20%Companion Animal Health
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Ceva's VECTORMUNE technology — which uses herpesvirus of turkeys (HVT) as a viral vector to express Newcastle disease and avian influenza antigens — is built on the same recombinant viral vector platform principle used in human adenoviral-vector vaccines (AstraZeneca COVID, J&J). The poultry vaccine industry effectively industrialized live viral vector vaccine manufacturing decades before it became prominent in human medicine, and companies like Ceva hold significant IP and manufacturing scale in the technology. As One Health surveillance frameworks treat zoonotic threats (H5N1, Newcastle, Salmonella) as shared human-animal risks, Ceva's poultry vaccine manufacturing capacity is now explicitly considered dual-use infrastructure in EU pandemic preparedness planning.
Ceva Sante Animale ↗Concentration2023
Ceva Santé Animale (Libourne, France) is a privately held animal health company controlled by a French management buyout team backed by Goldman Sachs and PAI Partners. Unlike Zoetis (public) or Boehringer Ingelheim (family-owned German), Ceva has no public financial reporting, making supply chain capacity assessment and financial stability assessment extremely difficult. Ceva is one of the top 5 global animal health companies with approximately €1.7B revenue, but its manufacturing capacity, inventory levels, and financial resilience are opaque to supply chain analysts.
Ceva Santé Animale ↗Origin2023
Ceva Sante Animale was founded in 1999 when Marc Prikazsky led a management buyout of Sanofi's veterinary division with backing from a French private equity consortium. The company was structured from the outset as a managers-and-employees-owned entity, unusual for a business that grew to €1.7 billion in revenue. Ceva's growth strategy was to acquire regional animal health companies globally (100+ acquisitions in 25 years) rather than relying on internal R&D, building geographic breadth especially in emerging markets (Brazil, China, India) where the larger US/German animal health multinationals had weaker footholds.
Ceva Sante Animale ↗